64CU-DOTA-ECL1i

N/A

Report date: 2025/11/20 16:00:55

NME

Base Information

Drug Name64CU-DOTA-ECL1i

Drug Alias NameN/A

ClassificationDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Copper > 64Cu +[5]

Mechanisms of ActionPositron-emission tomography enhancersC-C motif chemokine 2 inhibitors

TargetsC-C motif chemokine 2

Therapy Area/IndicationsArteriosclerosisHeart DiseasesCarotid Artery Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesWashington University School Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of Medicine

Inactive CompaniesN/A

Active IndicationsArteriosclerosisHeart DiseasesCarotid Artery Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A